Cargando…
A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers
A novel, fast and sensitive LC–MS/MS method was developed and validated for the bioanalysis of the antiviral agent favipiravir (FAV); a promising candidate for treatment of SARS-CoV-2 (COVID-19) in human plasma using pyrazinamide as an internal standard (IS). Simple protein precipitation was adopted...
Autores principales: | Morsy, Mosaad I., Nouman, Eman G., Abdallah, Youmna M., Zainelabdeen, Mourd A., Darwish, Mohamed M., Hassan, Ahmed Y., Gouda, Amira S., Rezk, Mamdouh R., Abdel-Megied, Ahmed M., Marzouk, Hoda M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015396/ https://www.ncbi.nlm.nih.gov/pubmed/33831737 http://dx.doi.org/10.1016/j.jpba.2021.114057 |
Ejemplares similares
-
A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers
por: Gouda, Amira S., et al.
Publicado: (2022) -
A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling
por: Marzouk, Hoda M., et al.
Publicado: (2022) -
A POPULATION PHARMACOKINETIC MODELING APPROACH TO EVALUATE THE CURRENT DOSING RECOMMENDATIONS OF FAVIPIRAVIR IN EGYPTIAN SUBJECTS
por: Salem, A., et al.
Publicado: (2023) -
Determination of lercanidipine in human plasma by an improved UPLC–MS/MS method for a bioequivalence study()
por: Chaudhary, Darshan V., et al.
Publicado: (2016) -
Quantification of Lumefantrine in Human Plasma Using LC-MS/MS and Its Application to a Bioequivalence Study
por: Pingale, Satish G., et al.
Publicado: (2013)